TABLE 3.
Cross-reactivity of WNV NS5 and E protein with SLE patient sera
| Samplea | MFI
|
PRNT titer
|
||
|---|---|---|---|---|
| NS5b | E proteinc | SLE virus | WNV | |
| 1A | 550 | 953 | 640 | 40 |
| 1B | 892 | 1,347 | 1,280 | 40 |
| 2A | 1,081 | 437 | 320 | <10 |
| 2B | 606 | 272 | 320 | <10 |
| 3A | 7,314 | 492 | 320 | 20 |
| 3B | 5,894 | 982 | 640 | 40 |
| 4A | 1,157 | 522 | 640 | 10 |
| 4B | 2,315 | 828 | 1,280 | 40 |
| 5A | 643 | 1,582 | 640 | <10 |
| 5B | 576 | 1,185 | 1,280 | <10 |
| 6A | 924 | 329 | 10 | <10 |
| 6B | 2,093 | 1,020 | 1,280 | 10 |
| 7A | 858 | 456 | 20 | <10 |
| 7B | 738 | 214 | 320 | 10 |
| 8A | 215 | 59 | 40 | <10 |
| 8B | 324 | 323 | 640 | 20 |
| 9A | 834 | 378 | 80 | <10 |
| 9B | 631 | 550 | 160 | 10 |
| 10A | 751 | 196 | 10 | <10 |
| 10B | 1,272 | 284 | 40 | <10 |
| 11A | 778 | 688 | 160 | 10 |
| 11B | 691 | 715 | 320 | 20 |
| 12A | 733 | 864 | 640 | 40 |
| 12B | 1,148 | 1,388 | 640 | 20 |
| 13A | 734 | 966 | 320 | <10 |
| 13B | 1,731 | 1,645 | 320 | <10 |
| 14A | 931 | 409 | 160 | 10 |
| 14B | 802 | 415 | 160 | 10 |
| 15A | 1,241 | 522 | 40 | <10 |
| 15B | 586 | 678 | 320 | 10 |
| 16A | 980 | 3,057 | 5,120 | 640 |
| 16B | 1,420 | 2,740 | 2,560 | 640 |
| 17A | 1,328 | 1,490 | 5,120 | 1,280 |
| 17B | 1,912 | 2,845 | 1,280 | 2,560 |
| 18A | 175 | 1,679 | 40 | <10 |
| 18B | 188 | 1,476 | 80 | <10 |
| 19A | 398 | 489 | 40 | <10 |
| 19B | 628 | 687 | 160 | <10 |
| 20A | 1,281 | 591 | 640 | 10 |
| 20B | 2,296 | 637 | 1,280 | <10 |
Twenty pairs of acute-phase (A) and convalescent-phase (B) sera from SLE-infected individuals were tested.
The cutoff for positivity for NS5 is 4,366. There were 2 positive samples out of 40 (5%).
The cutoff for positivity for E protein is 1,084 (Wong et al., submitted). There were 11 positive samples out of 40 (28%).